Alessandri et al. “Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation.” PLoS ONE 6, no. 9 2011: e25683. DOI: 10.1371/journal.pone.0025683.
Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.
Brito et al. “Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.” Leukemia Research 35, no. 9 2011: 1233-1240. DOI: 10.1016/j.leukres.2011.01.011.
Heightman, Tom D. “Therapeutic prospects for epigenetic modulation.” Expert Opinion on Therapeutic Targets 15, no. 6 2011: 729-740. DOI: 10.1517/14728222.2011.561786.
Mahadevan et al. “A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.” Annals of Oncology 22, no. 9 2011: 2137-2143. DOI: 10.1093/annonc/mdq734.
Paul N. Mortenson and Christopher W. Murray. “Assessing the lipophilicity of fragments and early hits.” Journal of Computer-Aided Molecular Design 25, no. 7 2011: 663-667. DOI: 10.1007/s10822-011-9435-z.
Podesta et al. “Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.” Leukemia Research 35, no. 9 2011: 1273-1275. DOI: 10.1016/j.leukres.2011.05.022.
Qi et al. “AT9283, a novel aurora kinase inhibitor suppresses tumor growth in aggressive B-cell lymphomas.” International Journal of Cancer 2011. DOI: 10.1002/ijc.26324.
Santo et al. “Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide.” Clinical Cancer Research 17, no. 10 2011: 3259–71. DOI: 10.1158/1078-0432.CCR-10-3012.
Squires et al. “Potent, selective inhibitors of Fibroblast Growth Factor Receptor define Fibroblast Growth Factor dependence in pre-clinical cancer models.” Molecular Cancer Therapeutics 10, no. 22 2011: 1542-1552. DOI: 10.1158/1535-7163.MCT-11-0426.